NIH R01 · 2025
PROJECT SUMMARY Neoadjuvant and perioperative chemoimmunotherapy are the standard of care for the treatment of patients with resectable non-small cell lung cancer (NSCLC). Unfortunately, the majority of patients with resectable NSCLC do not benefit from neoadjuvant/perioperative immune checkpoint inhibitor (ICI)-based therapies for reasons that are unclear. Efforts to develop more effective treatment strategies that bypass therapeutic resistance have been hampered by our limited understanding of the mechanisms that govern response to ICIs and that thus could serve as validated biomarkers to guide neoadjuvant/perioperative ICI treatment. Our long-term objectives are to develop rational…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.